Melanoma News – Melanoma Research Victoria https://melanomaresearchvic.com.au Fri, 25 Sep 2020 02:59:56 +0000 en-US hourly 1 https://melanomaresearchvic.com.au/wp-content/uploads/2017/12/cropped-favicon-32x32.png Melanoma News – Melanoma Research Victoria https://melanomaresearchvic.com.au 32 32 Emerging options for high-risk melanoma https://melanomaresearchvic.com.au/emerging-options-for-high-risk-melanoma Fri, 25 Sep 2020 02:58:50 +0000 https://melanomaresearchvic.com.au/?p=15684 An ongoing study is attempting to build on what researchers have learned in recent years regarding neoadjuvant approaches to immunotherapy for high-risk melanoma.

The post Emerging options for high-risk melanoma appeared first on Melanoma Research Victoria.

]]>
Source: Dermatology Times, August 2020

An ongoing study is attempting to build on what researchers have learned in recent years regarding neoadjuvant approaches to immunotherapy for high-risk melanoma.

With the increasing number of approved immunotherapies and targeted therapies for patients with stage 3 melanoma, accurate pathologic microstaging assumes increasing importance, says Giorgos Karakousis, M.D., associate professor of surgery at the Hospital of the University of Pennsylvania, Philadelphia.

“There have been ongoing discussions about the role and utility of sentinel lymph node (SLN) biopsy in patients with melanoma. But more so now than before, where a large part of the procedure’s value was prognostic, there is value in terms of helping guide decisions about effective adjuvant therapies,” he says.

READ THE ORIGINAL FULL ARTICLE

The post Emerging options for high-risk melanoma appeared first on Melanoma Research Victoria.

]]>
Garutti Examines Advantages of Neoadjuvant Approaches in Melanoma https://melanomaresearchvic.com.au/garutti-examines-advantages-of-neoadjuvant-approaches-in-melanoma Fri, 25 Sep 2020 02:56:01 +0000 https://melanomaresearchvic.com.au/?p=15682 The use of adjuvant therapies in melanoma could offer superior efficacy compared to what is currently provided by adjuvant therapies alone, with some preclinical data pointing to increased clinical benefit within this patient population, according to Mattia Garutti, MD.

The post Garutti Examines Advantages of Neoadjuvant Approaches in Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

The use of adjuvant therapies in melanoma could offer superior efficacy compared to what is currently provided by adjuvant therapies alone, with some preclinical data pointing to increased clinical benefit within this patient population, according to Mattia Garutti, MD.

“Especially in [patients with] stage III melanoma, the risk of relapse is really high,” said Garutti. “We need different strategies to increase cure rates for our patients. Neoadjuvant therapies in melanoma represent an exciting area of research. In other [diseases], such as breast cancer, the shift from the adjuvant to neoadjuvant therapy [has become] a gold standard. In melanoma, this shift is expected in the near future.”

Despite the advances that have been made with adjuvant therapies in recent years, patients with stage III melanoma still are at significant risk for relapse, Garutti and colleagues, wrote in a recent literature review.

READ THE ORIGINAL FULL ARTICLE

The post Garutti Examines Advantages of Neoadjuvant Approaches in Melanoma appeared first on Melanoma Research Victoria.

]]>
Melanoma ‘calculator’ for skin cancer risk https://melanomaresearchvic.com.au/melanoma-calculator-for-skin-cancer-risk Fri, 25 Sep 2020 02:49:54 +0000 https://melanomaresearchvic.com.au/?p=15680 Australians will now be able to determine their likelihood of developing melanoma in under a minute with a new lifetime risk ‘calculator’.

The post Melanoma ‘calculator’ for skin cancer risk appeared first on Melanoma Research Victoria.

]]>
Source: The Canberra Times, August 2020

Researchers at Melanoma Institute Australia have developed the online tool, and hope it will save lives by sparking early conversations between at-risk Australians and their doctors.

“No risk prediction is going to be absolutely perfect, but this is much better than anything else that’s available,” the institute’s co-medical director Richard Scolyer told AAP.

READ THE ORIGINAL FULL ARTICLE

The post Melanoma ‘calculator’ for skin cancer risk appeared first on Melanoma Research Victoria.

]]>
Predictors of long-term anxiety and depression in uveal melanoma survivors: A cross-lagged five-year analysis https://melanomaresearchvic.com.au/predictors-of-long%e2%80%90term-anxiety-and-depression-in-uveal-melanoma-survivors-a-cross%e2%80%90lagged-five%e2%80%90year-analysis Thu, 24 Sep 2020 07:59:41 +0000 https://melanomaresearchvic.com.au/?p=15671 Data were obtained from sample of 453 uveal melanoma survivors who completed observations 6?, 12?, 24?, 36?, 48? and 60?months postdiagnosis and missed no two consecutive observations.

The post Predictors of long-term anxiety and depression in uveal melanoma survivors: A cross-lagged five-year analysis appeared first on Melanoma Research Victoria.

]]>
Source: MDLinx, August 2020

As anxiety and depression are commonly reported in cancer survivors in long-term, researchers here examined three potential causal paths: (a) a direct path in which anxiety and depression arise due to concerns regarding physical symptoms and functional problems and fear of cancer recurrence (FCR) emerging during survivorship, (b) an indirect path whereby effects of concerns regarding physical symptoms and functional problems on anxiety and depression are mediated by FCR, and (c) a reciprocal path whereby anxiety and depression cause concerns regarding physical symptoms and functional problems and FCR, which aggravate later anxiety and depression.

Data were obtained from sample of 453 uveal melanoma survivors who completed observations 6-, 12-, 24-, 36-, 48- and 60-months postdiagnosis and missed no two consecutive observations.

READ THE ORIGINAL FULL ARTICLE

 

The post Predictors of long-term anxiety and depression in uveal melanoma survivors: A cross-lagged five-year analysis appeared first on Melanoma Research Victoria.

]]>
Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma https://melanomaresearchvic.com.au/dr-long-on-the-rationale-for-the-phase-3-combi-i-trial-in-braf-v600%c2%ac-mutant-melanoma Thu, 24 Sep 2020 07:51:14 +0000 https://melanomaresearchvic.com.au/?p=15663 Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

The post Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma appeared first on Melanoma Research Victoria.

]]>
Source: OncLive, August 2020

 

Georgina Long, BSc, PhD, MBBS, FRACP, co-medical director, Melanoma Institute Australia (MIA), chair of Melanoma Medical Oncology and Translational Research, MIA and Royal North Shore Hospital, University of Sydney, discusses the rationale for the phase 3 COMBI-i trial in BRAF V600­–mutant melanoma.

The COMBI-i study evaluated the combination of spartalizumab, dabrafenib (Tafinlar), and trametinib (Mekinist), says Long.

Findings from parts 1 and 2 of the phase 3 trial were presented during the 2020 ASCO Virtual Scientific Program and showed encouraging clinical activity and tolerability with the novel triplet.

READ THE ORIGINAL FULL ARTICLE

The post Dr. Long on the Rationale for the Phase 3 COMBI-i Trial in BRAF V600¬–Mutant Melanoma appeared first on Melanoma Research Victoria.

]]>
Disparities in the occurrence of late effects following treatment among adolescent and young adult melanoma survivors https://melanomaresearchvic.com.au/disparities-in-the-occurrence-of-late-effects-following-treatment-among-adolescent-and-young-adult-melanoma-survivors-2 Thu, 24 Sep 2020 07:45:05 +0000 https://melanomaresearchvic.com.au/?p=15661 Melanoma is the third most common cancer in the adolescent and young adult (AYA) population, however no studies have addressed the occurrence of adverse health conditions following melanoma treatment in these survivors.

The post Disparities in the occurrence of late effects following treatment among adolescent and young adult melanoma survivors appeared first on Melanoma Research Victoria.

]]>
Source: urbanhealthToday, August 2020

BACKGROUND: Melanoma is the third most common cancer in the adolescent and young adult (AYA) population, however no studies have addressed the occurrence of adverse health conditions following melanoma treatment in these survivors.

METHODS: Patients age 15-39 diagnosed with cutaneous melanoma from 1996-2012 and surviving ≤2 years were obtained from the California Cancer Registry and linked to statewide hospitalization data.

The influence of age at diagnosis, sex, race/ethnicity, neighborhood socioeconomic status (SES), health insurance, and surgery on the development of adverse health conditions was evaluated using Cox proportional hazards regression models.

READ THE ORIGINAL FULL ARTICLE

 

The post Disparities in the occurrence of late effects following treatment among adolescent and young adult melanoma survivors appeared first on Melanoma Research Victoria.

]]>
Discovering new bait for the immune system may lead to additional treatments for melanoma. Congratulations Andreas Behren, Katherine Woods, Jonathan Cebon, Stephen Wong and colleagues https://melanomaresearchvic.com.au/discovering-new-bait-for-the-immune-system-may-lead-to-additional-treatments-for-melanoma-congratulations-andreas-behren-katherine-woods-jonathan-cebon-stephen-wong-and-colleagues Wed, 23 Sep 2020 07:59:05 +0000 https://melanomaresearchvic.com.au/?p=15641 A collaborative study, led by ONJCRI and the Monash Biomedicine Discovery Institute (BDI) at Monash University, has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

The post Discovering new bait for the immune system may lead to additional treatments for melanoma. Congratulations Andreas Behren, Katherine Woods, Jonathan Cebon, Stephen Wong and colleagues appeared first on Melanoma Research Victoria.

]]>
Source: Olivia Newton-John Cancer Research Institute, September 2020

A collaborative study, led by ONJCRI and the Monash Biomedicine Discovery Institute (BDI) at Monash University, has uncovered new markers (HLA-associated peptides) that are uniquely present on melanoma tumours and could pave the way for therapeutic vaccines to be developed in the fight against melanoma.

Despite all improvements in melanoma treatment, every five hours one Australian dies because of the lack of effective treatment.

A promising new approach harnesses the body’s own immune system to detect and kill tumour cells, through recognition of small tumour specific protein fragments (peptides) that decorate the surface of the tumour cells. The study, published in Cancer Immunology Research, a journal of the American Association for Cancer Research, has successfully identified thousands of peptides uniquely present on melanoma tumours that can be recognised by the immune system.

READ THE ORIGINAL FULL ARTICLE

 

 

The post Discovering new bait for the immune system may lead to additional treatments for melanoma. Congratulations Andreas Behren, Katherine Woods, Jonathan Cebon, Stephen Wong and colleagues appeared first on Melanoma Research Victoria.

]]>
Albury Wodonga Regional Cancer Centre fundraising drive seeks 100 bearded ambassadors https://melanomaresearchvic.com.au/albury-wodonga-regional-cancer-centre-fundraising-drive-seeks-100-bearded-ambassadors Wed, 23 Sep 2020 06:14:42 +0000 https://melanomaresearchvic.com.au/?p=15647 Terry Greaves was feeling fit and healthy until the start of this year, when he was diagnosed with metastatic melanoma.

The post Albury Wodonga Regional Cancer Centre fundraising drive seeks 100 bearded ambassadors appeared first on Melanoma Research Victoria.

]]>
Source: ABC News, August 2020

Terry Greaves was feeling fit and healthy until the start of this year, when he was diagnosed with metastatic melanoma.

“It was all through my body. I had it in my brain, lungs, liver, bowel and in my bones, so it was stage four,” the 59-year-old said.

Doctors told him without treatment he would only have six weeks to live.

“It took me a while to get my head around it when they told me that, it was pretty devastating,” he said.

READ THE ORIGINAL FULL ARTICLE

The post Albury Wodonga Regional Cancer Centre fundraising drive seeks 100 bearded ambassadors appeared first on Melanoma Research Victoria.

]]>
The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (SEER) database (1975-2016) https://melanomaresearchvic.com.au/the-ongoing-racial-disparities-in-melanoma-an-analysis-of-the-surveillance-epidemiology-and-end-results-database-seer-database-1975-2016 Wed, 23 Sep 2020 06:04:41 +0000 https://melanomaresearchvic.com.au/?p=15644 Although the majority of cutaneous melanoma patients are non-Hispanic white (NHW), minorities consistently suffer worse melanoma specific survival (MSS). Much of the literature comes from analyses of registries from the 1990s and 2000s.

The post The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (SEER) database (1975-2016) appeared first on Melanoma Research Victoria.

]]>
Source: urbanhealthToday, August 2020

Although the majority of cutaneous melanoma patients are non-Hispanic white (NHW), minorities consistently suffer worse melanoma specific survival (MSS). Much of the literature comes from analyses of registries from the 1990s and 2000s.

OBJECTIVE: To evaluate whether and to what degree racial disparity in MSS persists since 2010.

METHODS: We analyzed 381,035 patients from the Surveillance, Epidemiology, and End Results (SEER) registry. Race categories included Hispanic, NHW, non-Hispanic black (NHB), non-Hispanic Asian or Pacific Islander (NHAPI), and non-Hispanic American Indian/Alaska Native (NHAIAN).

READ THE ORIGINAL FULL ARTICLE

The post The ongoing racial disparities in melanoma: an analysis of the Surveillance, Epidemiology, and End Results database (SEER) database (1975-2016) appeared first on Melanoma Research Victoria.

]]>
‘No tan is worth it’: young melanoma survivor’s sun safe message https://melanomaresearchvic.com.au/no-tan-is-worth-it-young-melanoma-survivors-sun-safe-message Mon, 21 Sep 2020 07:53:02 +0000 https://melanomaresearchvic.com.au/?p=15639 Launceston resident Kate von Stieglitz thought she was too young to be diagnosed with melanoma at 23 – but she was wrong.

The post ‘No tan is worth it’: young melanoma survivor’s sun safe message appeared first on Melanoma Research Victoria.

]]>
Source: The Examiner, September 2020

Launceston resident Kate von Stieglitz thought she was too young to be diagnosed with melanoma at 23 – but she was wrong.

After observing a suspicious-looking spot on her left quad, Ms von Stieglitz, now 24, went to two separate doctors who told her it was nothing to be concerned about.

However, after the spot became more prominent, she decided to seek a third opinion, booking an appointment with a specialist.

READ THE ORIGINAL FULL ARTICLE

The post ‘No tan is worth it’: young melanoma survivor’s sun safe message appeared first on Melanoma Research Victoria.

]]>